These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22695254)

  • 1. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.
    Amato RJ; Wilding G; Bubley G; Loewy J; Haluska F; Gross ME
    Clin Genitourin Cancer; 2012 Dec; 10(4):232-8. PubMed ID: 22695254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
    Meulenbeld HJ; de Bono JS; Tagawa ST; Whang YE; Li X; Heath KH; Zandvliet AS; Ebbinghaus SW; Hudes GR; de Wit R
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):909-16. PubMed ID: 23921574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
    Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
    J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.
    Kruczek K; Ratterman M; Tolzien K; Sulo S; Lestingi TM; Nabhan C
    Br J Cancer; 2013 Oct; 109(7):1711-6. PubMed ID: 24008662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
    Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
    BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
    Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
    J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
    de Bono JS; Molife LR; Sonpavde G; Maroto JP; Calvo E; Cartwright TH; Loesch DM; Feit K; Das A; Zang EA; Wanders J; Agoulnik S; Petrylak DP
    Ann Oncol; 2012 May; 23(5):1241-1249. PubMed ID: 21903605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
    Colombo N; McMeekin DS; Schwartz PE; Sessa C; Gehrig PA; Holloway R; Braly P; Matei D; Morosky A; Dodion PF; Einstein MH; Haluska F
    Br J Cancer; 2013 Mar; 108(5):1021-6. PubMed ID: 23403817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
    Squillace RM; Miller D; Wardwell SD; Wang F; Clackson T; Rivera VM
    Int J Oncol; 2012 Aug; 41(2):425-32. PubMed ID: 22614157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
    Floc'h N; Kinkade CW; Kobayashi T; Aytes A; Lefebvre C; Mitrofanova A; Cardiff RD; Califano A; Shen MM; Abate-Shen C
    Cancer Res; 2012 Sep; 72(17):4483-93. PubMed ID: 22815528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
    Agus DB; Sweeney CJ; Morris MJ; Mendelson DS; McNeel DG; Ahmann FR; Wang J; Derynck MK; Ng K; Lyons B; Allison DE; Kattan MW; Scher HI
    J Clin Oncol; 2007 Feb; 25(6):675-81. PubMed ID: 17308272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
    Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
    Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
    Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
    Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
    Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
    Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The postchemotherapy PSA surge syndrome.
    Thuret R; Massard C; Gross-Goupil M; Escudier B; Di Palma M; Bossi A; de Crevoisier R; Chauchereau A; Fizazi K
    Ann Oncol; 2008 Jul; 19(7):1308-1311. PubMed ID: 18356135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
    Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
    Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
    J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
    Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
    Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.